Restasis vs Miebo
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Restasis | US Miebo | |
|---|---|---|
| Generic name | cyclosporine ophthalmic emulsion | perfluorohexyloctane |
| Drug class | Calcineurin Inhibitor (Eye Drop) | Semifluorinated Alkane (Eye Drop) |
| Treats | Chronic dry eye | Dry eye disease |
| Category | Eye Health | Eye Health |
| Manufacturer | AbbVie (Allergan) | Bausch + Lomb |
| Year approved | 2003 | 2023 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $100M | — |
| Common side effects | Burning sensation, Eye redness, Watery eyes, Blurred vision | Blurred vision, Eye redness, Temporary discomfort on application |
Frequently asked questions
Is Restasis or Miebo better?
Neither is universally "better." Restasis (cyclosporine ophthalmic emulsion) and Miebo (perfluorohexyloctane) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Restasis and Miebo?
Restasis is a Calcineurin Inhibitor (Eye Drop) made by AbbVie (Allergan), while Miebo is a Semifluorinated Alkane (Eye Drop) made by Bausch + Lomb. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Restasis has the larger estimated TV advertising budget of the two.